Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Email Communication, February 3, 2010 - MenHibrix


Submission Type: BLA       Submission ID: 125363/0      Office: OVRR Product:
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
GlaxoSmithKline Biologicals
Telecon Date/Time: 03-Feb-2010 12:51 PM           Initiated by FDA? No
Telephone Number: Communication Categorie(s):
1. Information Request
Author: JASON HUMBERT Telecon Summary:
Response to 2-2-10 IR regarding the polio assays
FDA Participants: Jason Humbert
Non-FDA Participants: Jody Gould, PhD
Telecon Body:
Hi Jason -
Following up on this query. I also just left a voicemail message for you at your office.
I had asked the lab to check on this and they confirmed the -----(b)(4)-------------------- was used in study 009. (Note: the -----(b)(4)-------------------- was also used in study 005.)
The -----(b)(4)------------- is specified in Table 6 of the 009 study report (p 109) and in the text discussion of the assays (p 110). The SOP and validation for this assay is provided in module 5. Table 2 of the synopsis is in error - apologies for the confusion this caused.
Please advise if you would like me to send an official clarification to the BLA or if this email will suffice.
Regards, Jody
Jody Ann Gould, PhD Head, Neisseria Vaccines
North American Regulatory Affairs
610-787-3765 (phone)
610-787-7063 (fax)

Page Last Updated: 09/24/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English